Navigation Links
Access Pharmaceuticals Demonstrates Ability to Significantly Reduce Glucose Levels in Pre-clinical Testing of Cobalamin(TM) Oral Insulin
Date:12/7/2007

DALLAS, Dec. 7 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced today that it has demonstrated the ability, using the company's proprietary Cobalamin(TM) technology, to significantly reduce glucose levels in an animal model of diabetes, through its oral insulin product candidate. Several formulations using Cobalamin, which is based upon the body's natural absorption of vitamin B12 in the gastrointestinal tract, were tested in an animal model of diabetes. Additional pre-clinical studies are planned.

Access has patents and formulations based on vitamin B12 attachment to polymers and nanoparticles which carry an attached or encapsulated drug. The vitamin B12 absorption mechanism transfers the macrostructure from the gut to blood, facilitating the absorption of drugs that otherwise could not be delivered orally. Access' Cobalamin(TM) technology has the potential to enable and improve oral bioavailability of active drugs which currently have to be administered by injection, including proteins, antibodies and siRNA.

"While Access already has proof-of-principle data using this technology with a variety of proteins and peptides, we are delighted to have attained preclinical study results which indicate that a meaningful pharmacological effect can be achieved," stated Dr. David P. Nowotnik, Access' Senior Vice President, Research and Development. "As a result of this very promising result, we plan to complete a short series of formulation optimization studies and then to select a clinical development candidate."

Access intends to develop the Cobalamin(TM) oral delivery technology in collaboration with other pharmaceutical and biotechnology companies. Access has in the past and continues to conduct sponsored research programs with leading pharmaceutical companies based on its Cobalamin technology. The company is also actively seeking additional partners for both its oral insulin and other potential program
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
2. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
3. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
4. Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
5. Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
6. Access Pharmaceuticals Announces Two Poster Presentations Reporting Significant Preclinical Data on ProLindac(TM) at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
7. Demand for Spanish-Language Cancer Web Materials Quadruples; Internet Resources and Access Remain Scarce
8. New Analysis from 14 Countries Identifies Drug Access Priorities to Achieve 2010 AIDS Treatment Target
9. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... 2015  ResMed Inc. (NYSE: RMD ) today announced ... the quarter was $423.0 million, a 10 percent increase compared ... increase on a constant currency basis). Net income was $91.2 ... ended December 31, 2013. Diluted earnings per share for the ...
(Date:1/22/2015)... 22, 2015  Bio-Techne Corporation (NASDAQ: TECH ) ... member of the new Simple Plex platform through its ... represents the re-branding of the previously acquired CyPlex instrument ... is a transformative immunoassay technology which integrates an innovatively ...
(Date:1/22/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) ... Diagnostics Market by Product, Application, Technology, End User - ... , The infectious disease diagnostics market is ... $18,156.2 million by 2019 from $12,422.8 million in 2014. ...
Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
... Fla., Nov. 18 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: ... phase II studies, ONSET/OFFSET and RESPOND for ticagrelor (BRILINTA(TM)) ... in Orlando, FL,(1,2) with ONSET/OFFSET study results being simultaneously ... The ONSET/OFFSET data showed that treatment with ...
... , MADISON, N.J., Nov. 18 Quest Diagnostics Incorporated (NYSE: ... and services, today announced that the Simplexa Influenza A H1N1 (2009) ... and is now available as a test kit for distribution to ... at MEDICA 2009, November 18 to 21, 2009, at the Dusseldorf ...
Cached Medicine Technology:Results From Two Phase II Trials Add to Understanding of Ticagrelor (BRILINTA(TM)) and How it Works in the Body 2Results From Two Phase II Trials Add to Understanding of Ticagrelor (BRILINTA(TM)) and How it Works in the Body 3Results From Two Phase II Trials Add to Understanding of Ticagrelor (BRILINTA(TM)) and How it Works in the Body 42009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name 22009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name 32009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name 42009 H1N1 Flu Test From Quest Diagnostics Now CE Marked For International Distribution Under The Simplexa(TM) Brand Name 5
(Date:1/22/2015)... Angelweddingdress is a famous wedding dress company offering many trendy ... on Facebook, Twitter, and Pinterest. The fans will have an ... lottery every week. , Moreover, the company has extended its ... Angelweddingdress homepage for more information. , Angelweddingdress is ...
(Date:1/22/2015)... 2015 A new white paper by ... person-centeredness in the long-term care environment as well as ... continuum. The paper, “The Power of Person-Centeredness in Long-Term ... practices of the patient, resident and family experience in ...
(Date:1/22/2015)... Joan Lunden, award-winning American journalist, beloved ... upcoming 32nd Annual Miami Breast Cancer Conference ... LLC (PER®) , shares that “a fast-growing, virulent” cancer ... she had not followed up her clean mammogram with ...
(Date:1/22/2015)... 22, 2015 Four years since the release of ... coincided with the marriage of Avasa & Matthew Love – the ... is scheduled for release through White Swan Records on February 24, ... is a sacred path available to all of us to walk ...
(Date:1/22/2015)... 22, 2015 Compare-autoinsurance.org has released a new blog ... an auto insurance policy . , Some types of ... should check the newly released blog post to see if their ... dangerously damaged vehicles are some of the cars that cannot be ...
Breaking Medicine News(10 mins):Health News:Angelweddingdress Invites Its Customers To Follow It On Facebook, Twitter, And Pinterest 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:Some Vehicles Cannot Be Covered By An Auto Insurance Policy! 2
... N.J., March 27 Zydus Pharmaceuticals announced today that ... and Drug Administration (FDA) for its Abbreviated New Drug ... and 200mg. This product is available for immediate ... patients 10 years old or older with partial onset ...
... Michigan, there are not enough jobs in manufacturing and ... to overshadow supply is health care, particularly physicians.The health ... difficulty of becoming a doctor have led to a ... projected to get worse, according to the Michigan State ...
... Stats show safety programs need to be extended to others ... (HealthDay News) -- Only one-third of people killed in fatal ... report shows. , The other two-thirds of victims are passengers, ... to the AAA Foundation for Traffic Safety. , "For every ...
... Women,s Voices for the Health Care We NeedNEW YORK, March ... debate the merits and costs of health reform, women around ... our families. For many women and our families, health reform ... York City will speak out publicly about the problems they ...
... of a program established in Uganda last year, the ... (HVO) have again partnered to launch a new hematology ... Empresa De Seguros De Salud (EsSalud). The goal of ... clinicians, laboratory technicians, technologists, and students. This training will ...
... unlocks the virus from latent state , , FRIDAY, March 27 ... in the ongoing quest for a treatment, and possibly a ... as VP16 is apparently responsible for pushing herpes out of ... , Experts estimate that 70 percent to 90 percent of ...
Cached Medicine News:Health News:As Physician Shortage Looms, Recognize Your Doctor On March 30, National Doctors' Day 2Health News:Most Fatalities in Teen Crashes Are Not the Drivers 2Health News:Women's Speak-Out for Action on Health Care Reform 2Health News:ASH and HVO Partner to Launch Hematology Program in Peru 2Health News:ASH and HVO Partner to Launch Hematology Program in Peru 3Health News:Treatment Target for Herpes Pinpointed 2
Can download data from your A&D balance directly to your PC saving time and reducing the chances of manually recording the wrong weighing data; 60 month warranty; automatic adjustable environment set...
... is a fully automated genetic analysis system. ... with a patented linear polyacrylamide (LPA) gel, ... voltage program, and analyzes the data. Software ... and even customize automated data assessment. All ...
Coated-Tube (CT) RIA kit for the determination of autoantibodies to the TSH receptor (TSHR) in serum...
... an 125I radioimmunoassay designed for,in ... quantitative,measurement of estradiol in serum, ... in girls,and gynecomastia in men, ... amenorrhea. It is,also intended for ...
Medicine Products: